Trials / Unknown
UnknownNCT04356118
Efficacy and Safety of Recombinant Human Endostatin in Non-Small Cell Lung Cancer With Leptomeningeal Metastasis
- Status
- Unknown
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 30 (estimated)
- Sponsor
- Hui Bu · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to observe the clinical effect and safety of Recombinant Human Endostatin in non-small cell lung cancer with leptomeningeal metastasis
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Recombinant Human Endostatin | endostatin 7.5mg/㎡/d，Once a day for two weeks, take a week off,start the next cycle, up to four cycles .We advocate a highly individualized treatment plan according to each patients specific manifestations of the disease process. |
| DRUG | intrathcal methotrexate | Intrathecal chemotherapy specified dose on specified days. |
| DRUG | Targeted drugs for non-small cell lung cancer | EGFR Mutation: Erlotinib，Afatinib，Osimertinib, et al. ALK ROS1 Mutation:Crizotinib,Ceritinib,Alectinib ,et al. BARF Mutation:Vemurafenib,et al. Other Mutation: other Targeted drugs . |
Timeline
- Start date
- 2020-06-01
- Primary completion
- 2023-06-01
- Completion
- 2023-06-01
- First posted
- 2020-04-22
- Last updated
- 2020-05-27
Source: ClinicalTrials.gov record NCT04356118. Inclusion in this directory is not an endorsement.